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Selective blockers of the Kv1.5 channel have been developed for the treatment of
atrial fibrillation (AF), but little is known how these atrial-selective drugs affect human
action potentials (APs). Therefore we have investigated the Kv1.5 blocker MK-0448
(N-{6-[(1S)-1-(4-fluorophenyl)-2,2-di(pyridin-3-yl)ethyl]pyridin-2-yl}methanesulfon- amide) in
right atrial trabeculae from patients in sinus rhythm (SR), permanent AF (>6 months),
and intermittent AF. MK-0448 blocked Kv1.5 current in an expression system and
concentration-dependently elevated the plateau phase of atrial APs. In SR preparations
stimulated at 1Hz, MK-0448 (3μM) shortened action potential duration at 90% of
repolarization (APD90) and effective refractory period (ERP), but in permanent AF
preparations, MK-0448 prolonged APD90 and ERP. The effects of MK-0448 in intermittent
AF resembled those in SR preparations. Block of IKs is probably more prominent in AF
because of reduced repolarization reserve due to AF-induced remodeling.
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INTRODUCTION
In search of safer antiarrhythmic drugs for the treatment of atrial
fibrillation (AF), selective inhibitors of IKur have been designed
as atrial-selective class III antiarrhythmic agents with therapeu-
tic potential in AF. Since they target the Kv1.5 channels which
are functional only in atria (Mays et al., 1995), these agents are
considered to be devoid of proarrhythmic effects in ventricles
and hence have received a lot of interest in the scientific commu-
nity (for review see Ford and Milnes, 2008; Tamargo et al., 2009;
Ravens, 2010; Ravens and Wettwer, 2011).
We have previously investigated the electrophysiological effects
of several IKur inhibitors, including 4-aminopyridine, AVE0118,
XEN-D0101, all of which elevated the plateau phase of human
right atrial action potentials (APs) recorded in trabeculae of atrial
appendage obtained from patients in sinus rhythm (SR) or AF
(Wettwer et al., 2004; Christ et al., 2008; Ford et al., 2013).
Interestingly, action potential duration (APD90) and effective
refractory period (ERP) were shortened in SR but prolonged in
AF preparations.
Recently, first-time-in-man results with another selective
Kv1.5 inhibitor, MK-0448 were published (Pavri et al., 2012).
MK-0448 failed to affect relative atrial ERP in healthy volun-
teers, and the authors concluded that IKur block cannot be
expected to exert therapeutically useful antiarrhythmic effects
in AF. Since nothing is known about the effects of MK-0448
in ex-vivo human atrial tissue, we investigated its effects on
the shapes of atrial APs and ERP with standard microelectrode
techniques in trabeculae isolated from right atrial appendages
of patients in SR and AF, who had to undergo open heart
surgery. In SR preparations, MK-0448 elevated the plateau poten-
tial and shortened APD and ERP at 1Hz as expected from
IKur blockers. We also confirm that MK-0448 effectively blocks
Kv1.5 current in mouse fibroblasts stably expressing the hKCNA5
gene.
METHODS
MOUSE FIBROBLASTS
HK2BN9 cells expressing human Kv1.5 channels were kindly
provided by Dr. Tamkun (Snyders et al., 1993). The cells were cul-
tured in Dulbecco’s modified eagle medium containing 10% fetal
calf serum and 1% penicillin/streptomycin under atmospheric
conditions of 5% CO2 at 37◦C. 250μg/ml G418 was added to
the medium for selection. Expression of Kv1.5 was induced by
treating the cells with 1μM dexamethasone 24 h before an exper-
iment. The cells were studied with a standard single electrode
whole-cell voltage-clamp set-up as described previously (Radicke
et al., 2006). The bath solution contained (in mM): NaCl 150,
KCl 5.4, MgCl2 2, CaCl2 2.0, HEPES 10, glucose 10, pH 7.4, tem-
perature 25◦C. The electrode solution contained (in mM): KCl
40, potassium aspartate 80, NaCl 8, CaCl2 2, MgATP 5, EGTA 5,
GTP 0.1, HEPES 10, pH 7.4 adjusted with KOH. Series resistances
were between 5 and 10 M and were compensated by up to 85%.
Cell capacitance was measured with small hyperpolarizing clamp
steps from −40mV to −42mV, average value was 20.8 ± 1.2
pA/pF (n = 33) and did not differ between cells tested at 0.5 and
3Hz. Voltage clamp pulse generation, data collection and analysis
were performed with the ISO2 software (MFK, Niedernhausen,
Germany). Data were not corrected for the junction potential
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which was 11.7mV, as calculated with the JPCalc software (P.H.
Barry, Sydney, Australia).
PATIENTS’ DIAGNOSES AND MEDICATIONS
Atrial tissue was obtained from patients receiving cardiac surgery
because of coronary artery or valve disease. All patients gave
written informed consent. The study was approved by the ethic
committee of the Medical Faculty of Dresden University of
Technology (No. EK790799). The patients are listed in Table 1.
The study included 13 drug-exposed and 9 TMC preparations
from patients in sinus rhythm (SR group), 9 drug-exposed and
9 TMC preparations from patients with permanent atrial fib-
rillation (AF group, defined as permanent atrial fibrillation for
≥6 months at time of tissue collection), and 3 drug-exposed
preparations from patients with intermittent AF (episodes of
spontaneously terminating AF lasting for a few seconds up to
several hours). The medication of the patients typically included
ACE-inhibitors, β-blockers, nitrates, lipid-lowering drugs, and
diuretics.
EXPERIMENTAL SET-UP
Small pieces (50–100mg in weight) of human right atrial
appendages were transported to the laboratory in a spe-
cial Ca2+-free transport solution at 20–25◦C, composition in
Table 1 | Characteristics of patients whose trabeculae were used for
drug exposure.
SR Permanent AF Intermittent AF
n 22 17 5
male/female 19/3 12/5 5/0
Age, y 64.9 ± 2.0 71.5 ± 1.8 74.4 ± 1.6
BMI (kg m−2) 29.1 ± 1.1 30.1 ± 0.9 26.3 ± 0.9
Valve replacement, n 3 7 3
Bypass, n 17 6 1
Bypass and valve, n 2 4 1
Hypertension, n 19 16 4
Diabetes, n 6 9 0
Hyperlipidemia, n 9 11 2
Nicotin, n 5 1 0
CAD, n 19 11 2
LVEF, % 55.0 ± 2.9 47.5 ± 3.0 59.2 ± 4.5
MEDICATION, n
Digitalis 0 3 2
ACE-inhibitors 15 10 4
AT1-blockers 4 3 0
β-Blockers 19 17 3
Ca2+ channel blockers 2 2 2
Diuretics 8 8 2
Nitrates 4 0 0
Lipid-lowering drugs 15 13 4
Antiarrhythmic drugs 1 0 1
BMI, body mass index; CAD, coronary artery disease; LVEF, left ventricular ejec-
tion fraction; ACE, angiotensin-converting enzyme; AT1, angiotensin receptor-1
blocker.
mM: 100 NaCl, 10 KCl, 1.2 KH2PO4, 5 MgSO4, 50 tau-
rine, 5 MOPS, 30 2,3-butane-dione monoxime (BDM), pH
7.0. Either free-running trabeculae (<1mm in diameter and
2–5mm in length) or trabeculae together with attached atrial
wall were dissected and mounted on the bottom of a 5ml
organ bath perfused with 50ml of recirculating, oxygenized
Tyrode’s solution at a flow rate of 7ml/min at 36 ± 1◦C (com-
position in mM: 126.7 NaCl, 0.42 NaH2PO4, 22 NaHCO3,
5.4 KCl, 1.8 CaCl2, 1.5 MgCl2, pH 7.4 when equilibrated
with 5% CO2 in O2). Preparations were electrically stimu-
lated at a basal rate of 1Hz with isolated square-wave stimuli
of 1ms duration, 2 times threshold intensity. Transmembrane
potentials were recorded with glass microelectrodes filled with
2.5M KCl. Tip resistances of the electrodes were between
20 and 80M. Both timing of the driving stimuli and pre-
processing of the transmembrane potential responses were car-
ried out with a computer-aided action potential recording
system (Wettwer et al., 2004). Chart for Windows, Version
7.3.5, recording programme (ADInstruments Pty Ltd., Castle
Hill, Australia) was used for analysis of action potential
parameters.
Each experiment was preceded by a 60min equilibra-
tion period during which the preparations were allowed
to stabilize and residual BDM was completely washed out.
Numerical values of the main action potential parame-
ters had to remain constant, i.e., within a range of ±5%
for at least 10min. When the microelectrode moved out
of the cell, a new impalement was made at the same
place and the experiment was continued if the new record-
ing did not differ from the old one by visual judgment
and showed less than 3% difference upon final numerical
analysis.
MEASUREMENT OF EFFECTIVE REFRACTORY PERIOD
Effective refractory period (ERP) was measured by a single extra
stimulus interpolated after trains of 10 regular stimulation pulses
at the basal frequency of 1Hz with decreasing intervals in steps
of 5ms from the last regular pulse until the extra stimulus failed
to elicit an action potential. Following a short recovery period
the preparation was exposed to MK-0448 (3μM) at 1Hz for
another 60min and ERP was tested once more in the presence of
drug.
STOCK SOLUTIONS AND DRUG APPLICATION
MK-0448 was synthesized by Xention Ltd. Cambridge UK. In a
few experiments, MK-0448 was applied in cumulatively increas-
ing concentrations by directly adding aliquots from a 10mM
stock solution with DMSO as solvent to 50ml of the circulating
bath medium. The DMSO concentration never exceeded 0.2%, a
concentration which did not induce any significant change when
applied alone. Preparations were exposed to each concentration
of MK-0448 for 20min.
ANALYSIS OF ACTION POTENTIAL PARAMETERS
The following standard parameters of atrial APs were analyzed:
resting membrane potential, RMP (mV), action potential ampli-
tude, APA (mV), action potential duration at 20, 50, and 90%
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of repolarization, APD20, APD50 and APD90 (ms), maximum
rate of depolarization, dV/dtmax (V/s) and the “plateau poten-
tial” defined as the mean absolute membrane potential (mV)
in the time window between 20 and 30% of APD90 (PLT20).
Preparations with resting potentials less negative than −65mV
and amplitudes below 80mV were discarded.
STATISTICAL ANALYSIS
GraphPad Prism (version 4.03) was used for statistical analy-
sis. In the concentration-response curves (see Table 2) the values
obtained at increasing concentrations were compared to pre-
drug controls by One-Way ANOVA followed by Bonferroni’s
multiple comparison test. The individual action potential param-
eters of SR and permanent AF preparations in the presence of
3μM MK-0448 were compared to pre-drug controls by paired
Student’s t-test (see Table 3). Differences are considered statisti-
cally significant for P < 0.05.
RESULTS
EFFECTS OF MK-0448 ON Kv1.5 CURRENT
Kv1.5 currents, which was measured during step potential
changes from a holding potential of −60mV to various test
potentials between −40 and +80mV had a threshold poten-
tial of −30mV, activated rapidly and hardly inactivated within
500ms (data not shown). For drug testing we chose 50ms dura-
tion voltage-clamp steps to +50mV that elicited mean current
amplitudes of 85.0 ± 10.5 pA/pF at 0.5Hz (n = 16) and 110.6
± 16.9 pA/pF at 3Hz n = 17, P = 0.2133). MK-0448 (100 nM)
blocked Kv1.5 current amplitude in a frequency-dependent man-
ner (Figure 1A). At 0.5Hz, the block reached a steady-state
within 5–10min of drug application and partially recovered dur-
ing a 5-min period during which the cell was continuously
clamped at −60mV (Figure 1B). When cells were exposed to
MK-0448 during a 5min period held at −60mV, to main-
tain channels in the closed-state, IKv1.5 of the first post-rest
pulse was not different from pre-rest. Subsequent pulses in the
Table 3 | Effects of MK-0448 (3µM) on action potential parameters
and effective refractory period (ERP) of human right atrial trabeculae
from patients in SR and AF (stimulation frequency 1Hz).
SR
AP parameter Control, n = 6 MK-0448, 3µM, n = 6 Wash, n = 4
ERP (ms) 329.2± 15.8 293.3±19.4* 276.3±20.5
APD90 (ms) 318.2± 8.2 265.3±16.0* 251.8±20.3
APD50 (ms) 139.0± 9.7 176.5±11.6 116.3±40.8
APD20 (ms) 4.0± 0.6 53.2±22.0 25.1±22.0
PLT20 (mV) −16.0± 1.2 11.3±2.6*** −10.4±7.6
APA (mV) 98.7± 1.6 96.8±2.4 95.3±3.6
RMP (mV) −76.8± 1.4 −75.7±1.1 −76.5±1.2
dV /dtmax (V/s) 250.2± 26.9 263.8±39.7 283.0±31.5
Permanent AF
AP parameter Control, n = 4 MK-0448, 3µM, n = 4 Wash, n = 4
ERP (ms) 222.5± 13.1 295.0±19.3** 297.5±34.1
APD90 (ms) 218.3± 12.1 275.0±13.9* 271.0±16.5
APD50 (ms) 104.3± 12.4 190.0±10.9** 185.0±14.1
APD20 (ms) 35.7± 11.5 109.5±9.3*** 108.0±16.9
PLT20 (mV) −4.3± 4.5 14.9±4.4*** 1.1±11.6
APA (mV) 99.5± 2.3 98.5±3.3 97.5±4.6
RMP (mV) −79.5± 0.5 −76.8±2.0 −77.5±2.5
dV/dtmax(V/s) 237.5± 58.1 261.3±95.1 282.3±88.8
For abbreviations, see legend to Table 2. *P < 0.05, **P < 0.01, ***P < 0.001;
Paired Student’s t-test (drug vs. pre-drug control).
Table 2 | Concentration-dependent effects of MK-0448 at 1, 3, and 10µM (1Hz).
SR Control 1.0µM 3.0µM 10.0µM Wash
n = 5 n = 5 n = 5 n = 5 n = 4
APD90 (ms) 307.6±10.2 269.7±8.2 266.9±12.2 260.9±19.5 271.6± 13.7
APD50 (ms) 116.3±28.6 136.5±33.1 149.6±35.6 167.4±20.9* 154.6± 17.4
APD20 (ms) 5.4±1.5 51.3±20.5 92.0±23.2 92.5±23.8** 63.7± 25.3
PLT20 (mV) −20.4±3.4 −4.0±6.2*** +2.8±6.9*** +3.4±6.8*** −6.0± 6.7
APA (mV) 95.3±2.7 94.5±2.3 93.2±3.6 88.6±4.7 86.5± 7.2
RMP (mV) −74.2±1.9 −74.5±4.0 −72.8±3.5 −70.9±4.6 −70.0± 5.3
dV /dtmax (V/s) 300.8±24.4 267.3±29.8 269.2±27.9 191.8±58.3 186.3± 54.3
Permanent AF Control 1.0µM 3.0µM 10.0µM Wash
n = 5 n = 5 n = 5 n = 5 n = 5
APD90 (ms) 190.8±11.8 200.7±9.3 215.2±11.1 221.4±15.2* 222.9± 17.0
APD50 (ms) 101.6±7.4 125.7±7.5 143.1±8.4* 147.8±11.1** 145.9± 11.8
APD20 (ms) 31.8±8.8 55.7±4.0 73.4±5.8** 78.2±7.1** 71.7± 8.4
PLT20 (mV) −9.9±2.4 3.0±1.8* 9.5±2.2*** 11.6±4.3*** 4.7± 4.2
APA (mV) 100.9±3.6 104.0±2.2 101.4±3.7 98.2±6.7 96.9± 5.4
RMP (mV) −79.2±3.3 −78.9±2.6 −75.7±3.0 −70.9±3.9*** −74.6± 2.4
dV /dtmax (V/s) 211.0±36.4 204.0±40.9 177.8±23.6 147.3±32.2 200.1± 37.2
APD90, APP50, APD20, action potential duration at 90, 50, and 20% of repolarization, respectively; PLT20, average plateau potential at 20–30% of APD90; APA, action
potential amplitude; RMP, resting membrane potential; dV/dtmax . maximum rate of depolarization. Means ± s.e.m. from 5 experiments in which all concentrations
indicated were tested.
*P < 0.05, **P < 0.01, ***P < 0.001; One-Way-ANOVA followed by Bonferroni’s multiple comparison test (drug vs. pre-drug control).
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FIGURE 1 | Effects of MK-0448 on Kv1.5 currents measured in
HK2BN9 cells at 25◦C. (A) Voltage clamp and current traces
obtained before (black) and after superfusion of cells with 100 nM
MK-0448 (green) for 10min. Rate of clamp pulses as indicated. (B)
Onset of blocking effect of MK-0448 (100 nM) on peak Kv1.5 current
and recovery from block during 5min at holding potential of −60mV.
Individual current traces at top were obtained at the time points
indicated by small letters in the diary plot at the bottom. (C) Onset
of drug effect following exposure during 5min of continuous
clamping at −60mV. Step frequency: 3Hz.
presence of drug revealed a rapid onset of inhibition, increas-
ing with each pulse until reaching steady-state (Figure 1C).
MK-0448 (100 nM) reduced IKv1.5 from 82.3 ± 31.5 pA/pF to
22.4 ± 6.0 pA/pF (n = 5) within 3min of continuous voltage-
clamp steps at 0.5Hz, and from 113.8 ± 52.7 pA/pF to 12.9
± 2.5 pA/pF at 3Hz (n = 4). These results are consistent with
MK-0448 inhibition of Kv1.5 being contingent upon channel
activation.
EFFECTS OF MK-0448 ON ACTION POTENTIALS
Action potentials recorded in right atrial trabeculae from patients
in SR had the typical spike-and-dome configuration (Figure 2),
in permanent AF tissue the shape was triangular and is the result
of electrical remodeling [for review see (Dobrev and Ravens,
2003)]. Themost striking concentration-dependent effect of MK-
0448 (1–10μM) on SR action potentials at the basal stimulation
frequency of 1Hz was a robust elevation in plateau potential
(PLT20) (Figure 2; Table 2). In this set of experiments, the APD90
tended to be shortened (not significant) whereas APD20 and
APD50 were prolonged, reaching the level of statistical signif-
icance only at the highest concentration (see Table 2). Resting
membrane potential (RMP), action potential amplitude (APA)
and maximum depolarization velocity (dV/dtmax) were not sig-
nificantly affected by MK-0448 (see Table 2). Before and after
drug treatment all preparations followed the stimulation, even at
the highest concentration.
The effects of MK-0448 on ERP were studied only at 3μM.
This concentration produced maximum changes within 40–
50min of drug application, and these were partially reversible
after 60min of washout. In 6 preparations from patients in SR,
APD90, and ERP were significantly shortened (Figure 3; Table 3).
Similar effects were observed in 2 preparations from patients in
intermittent AF (Figure 3).
In permanent AF trabeculae, MK-0448 also significantly ele-
vated the plateau potential to a similar extent as in SR, but in
contrast to SR, prolonged APD at the three analyzed repolariza-
tion levels (Figures 2, 3; Table 3). In permanent AF preparations,
APA, RMP, and dV/dtmax were also not significantly affected, with
exception of RMP with 10μMMK-0448.
Because of limited available we could only study the effects
of MK-0448 in 2 trabeculae from patients in intermittent
AF, a typical recording is shown in Figure 3; 3 others were
used as TMCs. Similar to the results in SR preparations, MK-
0448 shortened APD90 and ERP in the 2 intermittent AF
preparations.
In time-matched control experiments with tissue from
patients in SR, intermittent AF, and AF, action potential parame-
ters did not change significantly (data not shown).
DISCUSSION
The characteristic changes in action potential parameters
observed with MK-0448 in human right atrial trabeculae are con-
sistent with block of Kv1.5 channels as reported previously for
several drugs [e.g., 4-AP, (Wang et al., 1993; Amos et al., 1996);
DPO-1, (Regan et al., 2006); AVE-0118, (Christ et al., 2008);
XEN-D0101, (Ford et al., 2013)].
MK-0448 was described as highly selective for expressed Kv1.5
channels [IC50 ∼10 nM; (Pavri et al., 2012)] over a wide variety
of standard cardiac ion channels. hERG channels are about
10,000-fold, inward rectifier current Kir2.1 and Kir3.1/3.4 about
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FIGURE 2 | Concentration-dependent effects of MK-0448 on action
potentials recorded in right atrial trabeculae from patients in
sinus rhythm (SR) and permanent atrial fibrillation (AF). Top:
Individual tracings for typical experiments, recorded in the presence
of increasing concentrations of compound (see color code). Exposure
time at each concentration: 20min; control: pre-drug control. Middle
and bottom: Mean values ± s.e.m. from 7 experiments in SR and
5 in AF, of action potential duration at 90, 50, and 20% of
repolarization (APD90, APD50, and APD20) and plateau potential
(PLT20). Frequency of stimulation: 1Hz. Please note, that not all
preparations were exposed to the full range of concentrations
(numbers of preparations indicated in brackets).
FIGURE 3 | Effects of MK-0448 (3μM, red trace, arrow) on action
potentials recorded in right atrial trabeculae from patients in
sinus rhythm (SR), intermittent atrial fibrillation (iAF) and chronic
atrial fibrillation (AF). Original recordings from one preparation in
each group is shown. c, pre-drug control (black trace). Stimulation
frequency 1Hz.
1000-fold, and Kv7.1 (IKs) some 10- to 100-fold less sensitive
than Kv1.5 (Pavri et al., 2012). The voltage-clamp data in a het-
erologous expression system confirm that MK-0448 (100 nM)
produced a robust block of human Kv1.5 with a rather slow onset
of action and partial recovery from block at −60mV. Although
our results do not allow precise characterization of drug-channel
interaction they clearly indicate that resting channels recover
from block and activation is necessary for development of
block, suggesting preferential binding to open and/or inactivated
channels.
In previous experiments, we demonstrated that low concentra-
tions of 4-aminopyridine selectively inhibit Iso (IKur) in human
atrial myocytes (Wettwer et al., 2004). This blocker elevated the
plateau potential in SR preparations (EC50 ∼15μM). In addition,
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4-AP at concentrations that are considered to be selective for IKur
block significantly shortened APD90 in SR but prolonged APD90
in permanent AF trabeculae (Wettwer et al., 2004). The most
prominent effects ofMK-0448 on human atrial APs, i.e., elevation
of plateau potential, shortening of APD90 in SR and prolongation
of APD20,APD50 and APD90 in permanent AF, are in line with our
previous findings with other IKur inhibitors, so that we are confi-
dent to conclude that MK-0448 does indeed block IKur in human
atrial trabeculae.
Unlike inhibition of hERG channels, inhibition of IKs was
not associated with a proarrhythmic ventricular effect in animal
models (Lynch et al., 1999). Nevertheless, modulation of IKs by
MK-0448 could also reduce repolarization reserve in the ventri-
cle and become arrhythmogenic in ventricles under appropriate
conditions (Lynch et al., 1999). It is important to note that it is
difficult to assess the ventricular proarrhythmic risk of a drug that
modulates IKs in healthy volunteers with normal ventricular repo-
larization reserve. Therefore, the atrial selectivity of MK-0448
would need to be carefully assessed in patients.
The shortening of APD90 and ERP by Kv1.5 blockers in SR is
proposed to be caused by the marked elevation of the plateau
potential in to a voltage range where more hERG channels
are activated, and, though inactivated rapidly, can recover from
inactivation at more negative potentials and thus hasten final
repolarization (Gintant, 2000).
Besides distinct alterations in shapes of action potentials, loss
of rate-adaptation of ERP and APD90 to frequency has been rec-
ognized as a hallmark of atrial remodeling both in patients (e.g.,
Attuel et al., 1982; Daoud et al., 1996) and in ex vivo studies (Franz
et al., 1997; Dobrev and Ravens, 2003). In our present study and
in the recent “first-time-in-human” study with MK-0448 all elec-
trophysiological testing was in a frequency range much below that
of AF and one could argue that based on our SR data that it is
not surprising that MK-0448 did not prolong AERP in healthy
volunteers (Pavri et al., 2012).
Experimental and clinical evidence suggests that atrial
fibrillation is due to micro-reentry triggered by ectopic foci
located in the proximity of the pulmonary veins (Haissaguerre
et al., 1998). Pharmacological interventions for interrupting
micro-reentry have to prolong the effective refractory period,
whilst suppression of ectopic foci requires reduction of excitabil-
ity. Provided that MK-0448 does indeed selectively block IKur, it is
more likely to increase atrial refractoriness (in AF) than to reduce
excitability, although it is not clear how the marked elevation of
the plateau amplitude relates to the prolongation of ERP in AF. It
must be emphasized, however, that the overall shape of the car-
diac action potential is determined by multiple ion conductances,
hence interpretation of action potential data cannot be conclu-
sive with respect to which ion channels contribute to a particular
change.
In SR, we even observed shortening of the ERP with MK-0448
and we cannot judge whether this is an anti- or proarrhyth-
mic effect in the atria. Indeed this can only be answered in a
prospective Phase 2 trial in AF patients. However, it is worth
noting that no proarrhythmia was reported for MK-0448 (Pavri
et al., 2012) or shortening of AERP in healthy volunteers. Other
Kv1.5 inhibitors, e.g., XEN-D0101, that have been evaluated
in the clinic have also not reported pro-arrhythmia (atrial or
ventricular) in healthy volunteers (Ford et al., 2013). Genetic
studies revealed an association of “loss-of-function” mutations
in the KCNA5 gene encoding for Kv1.5 with familial “lone” AF
(Olson et al., 2006). However, in this study there was incomplete
genotyping/phenotyping of family members and no evidence
for primary linkage. Indeed, the likelihood of observing these
data by chance alone is between 10 and 15%. A recent study
of more than 300 patients with early-onset lone AF revealed
3 “gain-of-function” mutations in KCNA5 in addition to sev-
eral loss-of-function mutations, supporting the hypothesis that
AF susceptibility may be enhanced by either change in KCNA5
function (Christophersen et al., 2013).
STUDY LIMITATIONS
In some human atrial preparations, APD does not remain sta-
ble during prolonged superfusion with saline solutions (typically,
∼2 h).—The classification of patients into SR and AF may not
always be reliable, i.e., the SR groupmay include atrial tissue from
patients that have had unrecognized episodes of paroxysmal or
recent onset AF.
CONCLUSION
In summary, the IKur blocker MK-0448 consistently elevates the
action potential plateau in human atrial trabeculae irrespective of
the initial shapes of the control action potentials and whether the
preparations were obtained from patients in SR or permanent AF.
In SR preparations, MK-0448 produced shortening of APD90 and
ERP, but in permanent AF tissue, prominent APD90− and ERP-
prolonging effects were observed with the drug. For prevention
of persistent AF recurrence, prolongation of ERP by MK-0448 in
AF preparations is certainly a highly desirable mode of action that
may protect the atrial myocardium during the phase of reverse
remodeling after cardioversion although if due to IKs modulation
this may come at a risk of inducing ventricular proarrhythmia.
It remains to be determined if selective IKur drugs (i) are more
effective at prolonging ERP at higher atrial rates, (ii) pharma-
cologically convert recent onset AF, (iii) reducing AF burden in
paroxysmal AF, and (iv) prevent the recurrence of persistent AF.
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